Verrica reported Q4 net loss of USD 8.07 million, or USD 0.57 per share, compared with a year-earlier net loss that narrowed by 67%. Q4 total revenue was USD 5.09 million, including net product revenue of USD 3.72 million, which rose more than tripled on higher demand for YCANTH. For FY 2025, total revenue was USD 35.58 million, while net product revenue was USD 15.29 million, up 133%, and selling, general and administrative expense was USD 35.22 million, down 40% due mainly to lower YCANTH commercial activity costs. FY 2025 net loss was USD 17.89 million, or USD 1.68 per share, compared with a year-earlier net loss that narrowed by 77%. Verrica said it ended FY 2025 with USD 30.15 million in cash and cash equivalents, no outstanding debt, and expects its cash runway to fund operations into Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603110800PRIMZONEFULLFEED9669902) on March 11, 2026, and is solely responsible for the information contained therein.